Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
578
Stocks News & Analysis
stocks
This defensive ASX listed REIT offers a 5% yield
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
stocks
Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.60 | 95.80 | -1.07% |
| CAC 40 | 8,146.83 | 69.95 | -0.85% |
| DAX 40 | 25,736.24 | 309.13 | -1.19% |
| Dow JONES (US) | 50,198.17 | 561.25 | -1.11% |
| FTSE 100 | 10,551.17 | 138.70 | -1.30% |
| HKSE | 22,785.69 | 509.06 | -2.19% |
| NASDAQ | 24,429.88 | 101.50 | 0.42% |
| Nikkei 225 | 59,462.54 | 438.26 | 0.74% |
| NZX 50 Index | 14,247.25 | 17.04 | -0.12% |
| S&P 500 | 7,323.63 | 16.90 | -0.23% |
| S&P/ASX 200 | 8,730.40 | 91.40 | -1.04% |
| SSE Composite Index | 3,560.79 | 27.04 | -0.75% |